Department of Gastroenterology, Digestive Endoscopy Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai 200025, China.
Digestive Endoscopy Center, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China.
Hepatobiliary Pancreat Dis Int. 2018 Jun;17(3):257-262. doi: 10.1016/j.hbpd.2018.03.015. Epub 2018 Mar 29.
Endoscopic papillary balloon dilation (EPBD) for common bile duct (CBD) stones removal in Billroth II gastrectomy patients is feasible. However, the long-term outcomes of this technique are not clear. The aim of this study was to evaluate the procedural and long-term outcomes of EPBD for removal of CBD stones in Billroth II gastrectomy patients.
The records of patients with previous Billroth II gastrectomy referred for CBD stones removal with endoscopic retrograde cholangiopancreatography (ERCP) between July 1, 2008 and September 1, 2016 were retrospectively reviewed. The main outcomes of stone clearance, ERCP-related adverse events, and stone recurrence were analyzed.
A total of 83 patients with previous Billroth II gastrectomy underwent ERCP in our center were reviewed. Forty-nine consecutive patients with previous Billroth II gastrectomy referred to EPBD for removal of CBD stones underwent 59 ERCP procedures were enrolled in the end. The overall successful CBD stones clearance was achieved in 42 patients (85.7%). ERCP-related adverse events was in 3 ERCP procedures (5.1%). Severe complications, including perforation and bleeding, were not observed. Six of 49 patients (12.2%) had stone recurrence after a median period of 22.5 months (range 6-71 months) from the end of stone removal treatment. Female [odds ratio (OR) = 11.352; 95% confidence interval (95% CI): 1.040-123.912; P = 0.046] and previous mechanical lithotripsy (OR = 13.423; 95% CI: 1.070-168.434; P = 0.044) were significantly associated with stone recurrence.
At long-term follow-up, EPBD for removal of CBD stones appeared to be safe and effective in Billroth II gastrectomy patients. Female and previous mechanical lithotripsy may be risk factors for stone recurrence.
内镜下乳头球囊扩张术(EPBD)用于治疗毕罗氏Ⅱ式胃切除术后患者的胆总管(CBD)结石是可行的。然而,该技术的长期效果尚不清楚。本研究旨在评估 EPBD 治疗毕罗氏Ⅱ式胃切除术后 CBD 结石的手术过程和长期效果。
回顾性分析 2008 年 7 月 1 日至 2016 年 9 月 1 日期间因 CBD 结石接受内镜逆行胰胆管造影(ERCP)治疗的既往毕罗氏Ⅱ式胃切除术患者的病历。分析结石清除率、ERCP 相关不良事件和结石复发的主要结果。
共回顾了 83 例既往毕罗氏Ⅱ式胃切除术患者的 ERCP 记录。其中 49 例因 CBD 结石接受 EPBD 治疗的毕罗氏Ⅱ式胃切除术患者接受了 59 次 ERCP 治疗,纳入本研究。42 例(85.7%)患者 CBD 结石完全清除。3 例(5.1%)患者发生 ERCP 相关不良事件。未观察到严重并发症,包括穿孔和出血。49 例患者中有 6 例(12.2%)在结石清除治疗结束后中位时间 22.5 个月(6-71 个月)后出现结石复发。女性[比值比(OR)=11.352;95%置信区间(95%CI):1.040-123.912;P=0.046]和既往机械碎石术(OR=13.423;95%CI:1.070-168.434;P=0.044)与结石复发显著相关。
在长期随访中,EPBD 用于治疗毕罗氏Ⅱ式胃切除术后患者的 CBD 结石似乎是安全有效的。女性和既往机械碎石术可能是结石复发的危险因素。